Phase IA Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

• ClinicalTrials.gov Identifier: NCT05302271
• Recruitment Status: Recruiting
• First Posted: March 31, 2022
• Last Update Posted: July 18, 2022
• Sponsor: Weill Medical College of Cornell University
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Information provided by (Responsible Party): Weill Medical College of Cornell University

Study Description

Brief Summary:

The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, dose escalation study with a total of 10 participants.

Condition or disease	Intervention/treatment	Phase
Friedreich Ataxia; Cardiomyopathies; Cardiac Hypertrophy; Myocardial Fibrosis	Biological: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN; Drug: Prednisone	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 10 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: The clinical study design is a dose-escalation study with a cohort of n=10, 5 subjects at each of 2 doses to establish the safety of the investigational drug product. The vector will be delivered intravenously.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase IA Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
• Actual Study Start Date: February 22, 2022
• Estimated Primary Completion Date: December 31, 2028
• Estimated Study Completion Date: December 31, 2029

Arms and Interventions

Arm	Intervention/treatment
Experimental: First Dose Cohort; AAVrh.10hFXN will be administered intravenously.	Biological: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN; AAVrh.10hFXN will be administered intravenously.; Drug: Prednisone; All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.
Experimental: Second Dose Cohort; AAVrh.10hFXN will be administered intravenously.	Biological: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN; AAVrh.10hFXN will be administered intravenously.; Drug: Prednisone; All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.

Outcome Measures

Primary Outcome Measures :

1. Safety of AAVrh.10hFXN [ Time Frame: 5 Years ]
   To determine the safety of AAVrh.10hFXN, as measured by the number of subjects with any treatment-related adverse events for 5 years.

Other Outcome Measures:

1. Change in cardiopulmonary exercise testing [ Time Frame: 5 Years ]
2. Change in cardiac-relevant parameters in cardiac-magnetic resonance scans [ Time Frame: 5 Years ]
3. Change in cardiac-relevant parameters in echocardiograms [ Time Frame: 5 Years ]
4. Change in arrhythmias with 24-hour monitoring. [ Time Frame: 5 Years ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 40 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Males and females, age 18 to 40
• Willing and able to provide informed consent
• Definitive diagnosis of FA, based on clinical phenotype and genotype (GAA expansion on both alleles)
• >600 GAA repeats in intron 1 in at least one allele
• FARS and SARA neurologic scores consistent with diagnosis of Friedreich's ataxia
• Left ventricle ejection fraction (EF) measured by cardiac MRI of ≥45% to 75%

• Evidence of FA-related cardiac disease, must meet the following criteria: must be abnormal in ≥2 of the following parameters, at least one of which is an abnormal cardiac MRI left ventricular mass index or abnormal cardiopulmonary exercise test

  1. In the absence of other factors known to cause left ventricular hypertrophy, cardiac MRI left ventricular mass index >2 standard deviations above the normal range (males >84 gm/m2, females >69 gm/m2)
  2. Cardiopulmonary arm crank testing with assessment of VO2 max ≤20 mL/kg-min, peak VO2 ≥10 mL/kg-min while maintaining revolutions of ≥40/min. To insure consistency of effort, peak RER ≥1.0
  3. Cardiac MRI stroke volume index <45 mL/m2
  4. Cardiac MRI global longitudinal left ventricular strain <20%
  5. Serum high-sensitivity cardiac troponin above the normal range
• Fibrosis ≤5% in the left ventricular wall on late gadolinium enhancement cardiac MRI
• Resting O2 saturation ≥95%
• Serum neutralizing anti-AAVrh.10 titer <1:40
• Hematocrit >30%
• White blood cell levels within normal limits
• Normal prothrombin, partial thromboplastin time
• Normal liver-related serum parameters (ALT, AST, ALP, bilirubin); normal liver ultrasound and serum alpha fetoprotein
• Normal kidney function as assessed by plasma urea and creatinine; estimated GFR >30 mL/min/1.73m2
• No evidence of active infection of any types, including hepatitis virus (A, B or C), human immunodeficiency virus (HIV-1 and HIV-2), or SARS-CoV2
• Fertile individuals should utilize barrier birth control measures to prevent pregnancy for the duration of the study
• Individuals not receiving experimental medications or participating in another experimental protocol for at least 12 wk prior to entry to the study
• Capable of undergoing cardiac MRI
• No contraindications to receiving corticosteroid immunosuppression
• Must be fully vaccinated against SARS-CoV2 (for Pfizer and Moderna 2 vaccinations + booster; for Johnson & Johnson/Janssen 1 vaccination + booster)

Exclusion Criteria:

• Individuals receiving corticosteroids or other immunosuppressive medications
• Individuals with uncontrolled diabetes (glycated hemoglobin, HbA1c levels >7%)
• Genotype FA missense mutation on one or both alleles
• Evidence of infection defined by elevated white blood cell count, temperature >38.5̊ C, infiltrate on chest x-ray
• Decompensated heart failure (NY4A class III-IV at time of baseline clinical assessment)
• Hemoglobin <10 g/dl
• Absolute neutrophil count <1500 cells/mm3
• Platelet count <100,000 cells/mm3
• Hemodynamically unstable atrial or ventricular arrhythmias which require medical intervention
• Contraindication to cardiac MRI (e.g., non-MRI compatible pacemaker/defibrillator) or gadolinium (known or suspected hypersensitivity, glomerular filtration rate <30 mL/min/1.73m2)
• Any malignancy during the last five years, except basal cell skin cancer
• Unrelated clinical condition with life expectancy <12 months (prohibiting follow-up)
• Concomitant conditions (other than FA) known to produce left ventricular hypertrophy, including aortic stenosis, systemic hypertension (BP ≥140/90 on noninvasive blood pressure), or genetically mediated hypertrophic cardiomyopathy
• Use of oxygen supplementation
• Risk for thromboembolic disease, including history of thromboembolic disease hospitalization within the last 90 days, recent trauma and/or recent surgical procedure. If the history of thromboembolic disease is not definitive, the subject will be excluded if laboratory testing suggests a risk for thromboembolic disease because of mutations in the protein-S, protein C, antithrombin, factor V Leiden or prothrombin gene
• Any uncontrolled psychiatric disease
• Pregnant or breastfeeding woman
• Prior participation in any gene and/or cell therapy
• Known obstructive coronary artery disease (as documented by clinical history of myocardial infarction, prior coronary revascularization or angina symptoms (Canadian Cardiovascular Society grade ≥2 at time of baseline clinical assessment), or epicardial obstructive coronary artery disease (≥ 50% left main, ≥ 70% of other major coronary arteries)
• Any lung function abnormalities that would affect cardiopulmonary testing
• Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his/her participation in the study
• If prior infection with SARS-CoV2, any related residual cardiac or pulmonary abnormalities
• Alcoholism or drug addiction (see reference 71 for alcoholism, reference 72 for drug addiction)

Contacts and Locations

Contacts

Contact: Haley Bowe, BS; 646-962-4580; hab4007@med.cornell.edu

Contact: Noor Hasan, MBBS; 646-962-5583; noh4004@med.cornell.edu

Locations

United States, New York

Weill Cornell Medicine; Recruiting

New York, New York, United States, 10021

Contact: Haley Bowe, BS 646-962-2672 hab4007@med.cornell.edu

Contact: Noor Hasan, MBBS 646-962-5583 noh4004@med.cornell.edu

Principal Investigator: Ronald G Crystal, MD

Sponsors and Collaborators

Weill Medical College of Cornell University

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: Ronald G Crystal, MD; Weill Medical College of Cornell University

More Information

• Responsible Party: Weill Medical College of Cornell University
• ClinicalTrials.gov Identifier: NCT05302271
• Other Study ID Numbers: 20-01021274; R61HL151355 ( U.S. NIH Grant/Contract )
• First Posted: March 31, 2022
• Last Update Posted: July 18, 2022
• Last Verified: July 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Ataxia; Cerebellar Ataxia; Friedreich Ataxia; Cardiomyopathies; Cardiomegaly; Hypertrophy; Heart Diseases; Cardiovascular Diseases; Dyskinesias; Neurologic Manifestations; Nervous System Diseases; Cerebellar Diseases; Brain Diseases; Central Nervous System Diseases; Pathological Conditions, Anatomical; Spinocerebellar Degenerations; Spinal Cord Diseases; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Genetic Diseases, Inborn; Mitochondrial Diseases; Metabolic Diseases; Prednisone; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Antineoplastic Agents